Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Asandeutertinib and Osimertinib and Food Effect in Healthy Volunteers
NCT04798638Phase 1Completed
- Sponsor
- TYK Medicines
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of asandeutertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by TYK Medicines. Primary endpoints: Maximum Plasma Concentration (Cmax) of TY-9591 and its metabolites, Maximum Plasma Concentration (Cmax) of Osimertinib and its metabolites and 2 more. Started Apr 2021; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04798638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798638.